The stock of Metagenomi Inc (MGX) has gone down by -14.28% for the week, with a 13.64% rise in the past month and a -47.36% drop in the past quarter. The volatility ratio for the week is 7.71%, and the volatility levels for the past 30 days are 9.53% for MGX. The simple moving average for the last 20 days is -3.69% for MGX stock, with a simple moving average of -40.99% for the last 200 days.
Is It Worth Investing in Metagenomi Inc (NASDAQ: MGX) Right Now?
The 36-month beta value for MGX is also noteworthy at -0.65. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for MGX is 21.78M, and at present, short sellers hold a 12.68% of that float. The average trading volume of MGX on May 01, 2025 was 429.30K shares.
MGX) stock’s latest price update
Metagenomi Inc (NASDAQ: MGX)’s stock price has decreased by -13.29 compared to its previous closing price of 1.73. However, the company has seen a -14.28% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-17 that Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months
Analysts’ Opinion of MGX
Many brokerage firms have already submitted their reports for MGX stocks, with H.C. Wainwright repeating the rating for MGX by listing it as a “Buy.” The predicted price for MGX in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on May 07, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see MGX reach a price target of $6, previously predicting the price at $16. The rating they have provided for MGX stocks is “Neutral” according to the report published on May 02nd, 2024.
Wells Fargo gave a rating of “Overweight” to MGX, setting the target price at $25 in the report published on March 05th of the previous year.
MGX Trading at -13.75% from the 50-Day Moving Average
After a stumble in the market that brought MGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.65% of loss for the given period.
Volatility was left at 9.53%, however, over the last 30 days, the volatility rate increased by 7.71%, as shares surge +13.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.05% lower at present.
During the last 5 trading sessions, MGX fell by -13.76%, which changed the moving average for the period of 200-days by -69.39% in comparison to the 20-day moving average, which settled at $1.5580. In addition, Metagenomi Inc saw -58.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MGX starting from Wein Matthew, who sale 930 shares at the price of $1.87 back on Mar 05 ’25. After this action, Wein Matthew now owns 9,467 shares of Metagenomi Inc, valued at $1,744 using the latest closing price.
Wapnick Pamela, the Chief Financial Officer of Metagenomi Inc, sale 1,808 shares at $1.87 during a trade that took place back on Mar 05 ’25, which means that Wapnick Pamela is holding 59,684 shares at $3,390 based on the most recent closing price.
Stock Fundamentals for MGX
Current profitability levels for the company are sitting at:
- -1.7 for the present operating margin
- 0.95 for the gross margin
The net margin for Metagenomi Inc stands at -1.49. The total capital return value is set at -0.31. Equity return is now at value -34.69, with -22.64 for asset returns.
Based on Metagenomi Inc (MGX), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -2.38.
Currently, EBITDA for the company is -83.49 million with net debt to EBITDA at -0.22. When we switch over and look at the enterprise to sales, we see a ratio of 1.43. The receivables turnover for the company is 41.6for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.91.
Conclusion
In summary, Metagenomi Inc (MGX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
